Clay Siegall is President, Chief Executive Officer and Chairman of the Board of Immunome Inc. (IMNM). The company reported total compensation of $7,682,601 for fiscal year 2025.
| Salary | $735,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $6,272,810 |
| Non-equity incentive plan | $661,500 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $13,291 |
| Total | $7,682,601 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Immunome Inc. filed April 24, 2026, accession 0001140361-26-016685.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Clay Siegall this page | President, Chief Executive Officer and Chairman of the Board | $7,682,601 |
| Max Rosett | Chief Financial Officer | $2,785,557 |
| Robert Lechleider | Chief Medical Officer | $2,747,618 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Immunome Inc. compensation brief.
Clay Siegall's compensation sits inside Immunome Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.